Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular and Clinical Oncology
Join Editorial Board Propose a Special Issue
Print ISSN: 2049-9450 Online ISSN: 2049-9469
Journal Cover
July-2017 Volume 7 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
July-2017 Volume 7 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Asbestos-related lung cancers: A retrospective clinical and pathological study

  • Authors:
    • Marie Uguen
    • Jean‑Dominique Dewitte
    • Pascale Marcorelles
    • Brice Loddé
    • Richard Pougnet
    • Philippe Saliou
    • Marc De Braekeleer
    • Arnaud Uguen
  • View Affiliations / Copyright

    Affiliations: Department of Occupational and Environmental Diseases, Brest University Hospital, University of Brest, F‑29220 Brest, France, Department of Pathology, Brest University Hospital, University of Brest, F‑29220 Brest, France, Department of Public Health, Brest University Hospital, University of Brest, F‑29220 Brest, France, Laboratory of Neurosciences of Brest (EA4685), Faculty of Medicine, The University of Western Brittany, F‑29220 Brest, France
  • Pages: 135-139
    |
    Published online on: May 30, 2017
       https://doi.org/10.3892/mco.2017.1277
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Exposure to asbestos results in serious risks of developing mesothelioma and lung cancer. The link between asbestos exposure and lung carcinoma is well established. Nevertheless, precise histopathological data are poorly considered when investigating the asbestos‑cancer link in a compensatory approach. In the present study, we aim to describe the features of individuals with compensated lung cancer who were referred to an occupational disease center, regarding occupational exposure to asbestos, smoking history and pathological data. We led a retrospective study of compensated ARLC cases seen in our occupational disease center between 2003 and 2013. A total of 146 men were included (mean age at diagnosis, 63.2 years) of whom approximately 90% were heavy current or former smokers (mean value, 30.4 packs/year). The major industries associated with the lung cancer cases were shipbuilding (69.9%), and building construction (7.5%) in this harbor region. The results of the present study showed that lung upper lobe was most prevalent (61.6%) and an excess of adenocarcinoma was found (45.9%), followed by squamous cell carcinoma (38.4%) as well as thoracic sarcomas (2.1%). Neoplasm was not histologically proven in 6.8% of the cases. Subsequent pathology examinations also reclassified 2 tumors as metastases from esophageal and laryngeal origins. In conclusion, smoking prevention should be encouraged in asbestos‑exposed workers as reflected by the number of smokers with asbestos‑related lung cancer. Thus, histological data should be considered further to evaluate the potent relationship between asbestos exposure and lung malignancy, especially in a compensatory approach.

Introduction

Occupational lung cancer generates high mortality and is the most common cancer compensated in France (1). In 1997, the Helsinski criteria for identifying individuals with a high risk of asbestos exposure at work were accepted (2). Older studies found inconsistent results regarding the lobe of origin and histology of asbestos-related lung cancer (ARLC) (3). Some studies showed an upper lobe location similar to tobacco-related lung cancer, whereas other investigators found a lower lobe location (4–11). Although adenocarcinoma was found to be the most prevalent in some studies, a recent review of the literature by Nielsen et al (3) showed that there was no difference in location and cell type between ARLC and non-ARLC. They concluded that cell type and location of lung cancer were not useful for differentiating ARLC from other lung cancers. Prognosis of ARLC was not different from that of other lung cancers (3).

Presence of pleural plaques demonstrated a previous asbestos exposure but was not a precancerous condition. Asbestosis argued for high asbestos exposure and was associated with an increased risk of lung cancer (3). All asbestos types were associated with lung cancer (3).

Asbestos-exposed smokers had a higher risk of developing lung cancer compared with asbestos-exposed non-smokers. In fact, smoking was found to be the main risk factor but its interaction with asbestos was not totally clear (3). Some studies showed a multiplicative effect, whereas other studies suggested an additive model (12–15).

The present study investigated the occupational data of patients with compensated lung cancer, their smoking habits and histological subtype of lung cancer. The aim of the present study was also to discuss the criteria for warding occupational cancer compensation.

Patients and methods

After ethics approval was obtained from our institutional review board (CHRU Brest, 2016. CE10), we led a retrospective study based on financially compensated ARLCs identified in occupational disease center between 2003 and 2013. Data on occupational history and smoking habits were collected. Ex-smokers were defined as those who had ceased smoking at the time they consulted in our occupational disease center. Non-smokers were defined as those who had never smoked in their lifetime. Tumor location and histological subtype of lung cancer were noted according to the last pathological data. Patients who had two occupations were recorded separately.

The present study included 146 male patients of whom the majority (90%) were heavy current or former smokers (mean, 30.4 packs/year).

Results

Patient characteristics

In total, 146 male patients with a mean age at diagnosis of 63.2±9.9 years (range, 37–85 years) were included in the present study. Ex-smokers represented 79.5% (116/146) of the cohort, followed by smokers (10.3%, 15/146) and non-smokers (5.5%, 8/146). No data were available for 4.8% (7/146) of the patients. The mean consumption of ex-smokers and smokers was 30.4±16.9 packs/year.

Work-relatedness

Ship repair was the most prevalent occupational industry (69.9%, 102/146), followed by building construction (7.5%, 11/146), and electricity (4.8%, 7/146 (Table I). The most common types of job were maintenance and repair (mechanics, 38 cases), followed by electricity and cable setting (31 cases), welder (27 cases) and boiler-related jobs (7 cases). Thirteen patients had two types of industrial classification in their professional career. Regarding the frequency of asbestos-containing materials, thermal insulation was the most prevalent (64 cases), followed by asbestos dust on equipment (58 cases), seal coating (41 cases), thermal protection workstation (33 cases), and asbestos cement (25 cases) (Table II). The mean duration of asbestos exposure for lung cancer was 28.3±10.1 years, while the mean duration of the latency period was 10.5±8.6 years.

Table I.

Distribution of industries and jobs of patients with asbestos-related lung cancers.

Table I.

Distribution of industries and jobs of patients with asbestos-related lung cancers.

Type of exposureIndustrial classificationJob occupationNo. of workers

One type of industrial classification inpatients' professional career
Handling of asbestos-containing products during their jobBuilding constructionBricklayer/ carpenter (5) Plumber, sheet metal construction worker (1) Painter (1)10
Building construction (two job occupations quoted)Carpenter and cable setting man (1), Crane operator (demolition waste and brake lining assembler) and maintenance (1) Brake lining assembler/mechanic (1)
Handling of asbestos-containing products during their jobShip building and repairCarpenter (11), Mechanic (29), Boiler maker and installer (1),Welder (22), Storekeeper (1), Electricity and cable setting man (24) Maintenance (1), Painter (1) Details not provided (3)102
Ship building and repair (two job occupations quoted)Mechanic and boiler installer (1), Mechanic and carpenter (2), Carpenter and cable settingman (1), Painter and boiler installer (1), Truck driver and installer (2), Installer and storekeeper (1), Coppersmith and mechanic (1)
Handling of asbestos-containing products during their jobElectricity/ gas and steam powerInstaller (1), Electricity and cable setting man (4), Boiler installer (1), Mechanic and boiler installer (1), Coppersmith (1)7
Transportation servicesMaintenance and repairman (1)1
Using asbestos-containing products in manufacturing processManufacturing plastics and rubber materialsMechanic (2), Electricity and cable setting man (2),Welder (1), Working in co-activity (4)9
Details not providedDetails not provided (1), Plumber (1), Welder (2)4

Two types of industrial classification in patients' professional career

Handling of asbestos-containing products during their jobBuilding construction and ship buildingBricklayer and boiler installer (1), Maintenance and storekeeper (1), Welder (1), Carpenter and boiler installer (1), Plumber and welder (1)5
Building construction and electricity/gas steam powerMechanic, installer and boiler installer (1)1
Building construction and national defenseElectronics (1)1
Manufacture of motor vehicles and national defenseMechanic (brake lining assembler) (1)1
Ship building and national defensePainter (1)1
Ship building and water distribution installationInstaller and coppersmith (1)1
Handling of asbestos-containing products during their jobShip building andmanufacture of basic iron and steelWelder, installer and maintenance (1)1
Details not providedDetails not provided (2)2

Table II.

Distribution of asbestos-containing materials (no. of times where materials are quoted).

Table II.

Distribution of asbestos-containing materials (no. of times where materials are quoted).

Type of asbestos-containing materialsNo. of times where materials are quoted
Thermal insulation64
Asbestos dust on equipment58
Seal coating41
Thermal protection workstation33
Asbestos cement25
Individual thermal protection18
Waste17
Friction linings11
Flocking  9
Loose asbestos  3
Asbestos resin  1
Details not provided  5
Tumor localization

The tumor was located in the upper lobe in 61.6% (90/146) of the cases, followed by the lower lobe (21.2%, 31/146), the middle lobe (3.4%, 5/146), and lower and middle lobe associated with 2.1% (3/146). No data were available for 11.6 % of cases (17/146).

Histological cancer type

Adenocarcinoma was the most frequent cancer (45.9%, 67/146), followed by squamous cell carcinoma (38.4%, 56/146), small cell lung carcinoma (4.8%, 7/146), undifferentiated/sarcomatoid carcinoma lacking adenocarcinomatous or squamous differentiation (2.1%, 3/146), and sarcoma (without specification 1.4%, 2/146; dedifferentiated liposarcoma 0.7%, 1/146). One of the undifferentiated sarcomatoid carcinoma arose in the posterior mediastinum without lung tumor. Further pathological analyses reclassified two tumors as lung metastases of an esophageal adenocarcinoma and a primary laryngeal squamous cell carcinoma. There was no histological proof of cancer in 6.8% (10/146) of the cases, diagnosis being only based on radiological data (investigations refused by the patients, non-contributive or prevented by the patients' general condition).

Compensated ARLC

Diagnostic criteria of asbestos-related diseases were established in France in 1950 and 1996 and updated in 2000 (Tables of occupational diseases 30 and 30 bis). The main recognized non-cancerous asbestos- related diseases are asbestosis (Table 30 alinea A) and pleural thickening or pleural plaques (Table 30 alinea B). Recognized asbestos-related cancers are malignant mesothelioma (Table 30 alinea D) and primary lung cancer (Table 30 alinea C if associated with non-cancerous asbestos-related diseases with a requirement of exposition to asbestos for >5 years or Table 30 bis without other asbestos-related diseases but with a requirement of exposition to asbestos for >10 years).

In the present study, the patients represented 52.1% (76/146) and 46.6% (68/146) of compensated lung cancers in Tables 30 and 30 bis, respectively (no data for 2 patients). In addition, 49.3% of patients had pleural plaques (72/146) and 13% had pleural thickening (19/146), while 44.4% of the pleural plaques were located in the costo-vertebral gutters (32/72) and 12.5% on the diaphragm (9/72), 5.6% were located on the anterior wall (4/72) and 5.6% on the posterior wall (4/72). Atelectasis strips were only evident in 2.7% (4/146), asbestosis in 0.7% (1/146) and pleurisy in 4.1% (6/146).

Discussion

To the best of our knowledge, this is the first comprehensive study conducted in France on occupational asbestos exposure and lung carcinoma pathological features. The link between lung cancer and asbestos exposure is sometimes difficult to attest (16). Two criteria for this recognition are used in many countries (Germany, Austria, Belgium, Finland, Norway, Sweden and Switzerland): proved intense exposure (Helsinki criteria or threshold of 25 fibers/ml/year) and/or asbestos-related conditions (asbestosis and/or extensive modification of the pleura) (17). In France, occupational disease tables with specific criteria are used to determine whether or not lung cancer is asbestos-related (Tables 30 and 30 bis) or not. The diagnosis must be based on histological data or, if not available, on the basis of a clinical course and suggestive radiological data (17). Many differences regarding criteria exist between European countries for the recognition of ARLC (Table III) (17).

Table III.

European criteria for recognition of ARLC [(adapted from Eurogip. Les maladies professionnelles liées à l'amiante en Europe. 10–43. 1-1-2006). (1,17)].

Table III.

European criteria for recognition of ARLC [(adapted from Eurogip. Les maladies professionnelles liées à l'amiante en Europe. 10–43. 1-1-2006). (1,17)].

CountryMedical criteriaExposure criteriaLatency
FranceHistological examination or on the basis of radiological data and clinical course10 years (Table 30 bis) or 5 years (Table 30 alinea C) of exposure Limiting list of worksMaximum: 40 years after the end of exposure
GermanyLung cancer with asbestosis or pleural disease Alternative condition (see exposure criteria)Exposure of 25 fibers/ml/year (alternative condition to medical criteria)10 years at least No details provided
AustriaLung cancer with asbestosis or pleural disease Alternative condition (see exposure criteria)Exposure of 25 fibers/ml/year (alternative condition to medical criteria)
BelgiumAlternative conditions: Asbestosis or pleural thickening Under optical microscope: 500 asbestos bodies per gram of dry lung tissue or at least 5 asbestos bodies per ml of bronchoalveolar lavage Confirmed by electronic microscopy if doubt Under electron microscope:at least 5 million asbestos fibers longer than 1 µm per gram of dry lung tissue or at least 2 million amphibole fibers longer than 5 µm per gram of dry lung tissue Alternative criteria (see exposure criteria)Exposure of 25 fibers/ml/year Or limitative list of works Or medical criteria equivalent to exposure above 25 fibers/ml/year10 years
DenmarkBetter microscope diagnosis, otherwise probable diagnosis based on clinical presentation and course of the diseaseHelsinski criteriaDetails not provided
SpainLung cancer with asbestosis. If no asbestosis, diagnosis based on a biopsy, otherwise microscopic examination of the bronchoalveolar lavage10 years (except for lung cancer with asbestosis)10–20 years 10 years (if no asbestosis)
FinlandDiagnosis of a neoplasm of lung or bronchi by a pathologist. If asbestosis, automatic recognitionHelsinski criteria (if no asbestosis)
ItalyRadiologic examination (X-ray, CT-scan), blood tests, electrocardiogram, cytological examinationNo criteria regarding a minimum duration or intensity of exposureNo details provided
NorwayHistologic examination or on the basis of radiological data and clinical courseHelsinski criteria15 years
PortugalX-ray, CT-scan, bronchoscopy, biopsyIndicative list of works10 years
SwedenDiagnosis based on biopsy or cytology and X-ray Lung cancer with asbestosis or exposition criteriaAt least 15–20 years or above 10 fibers/ml/year15 years
SwitzerlandDiagnosis based on radiological, histological data or bronchoscopic findings. Recognition if lung cancer with asbestosis or pleural diseases or exposition criteria25 fibers/ml/year (alternative condition to medical criteria)No details provided

Shipbuilding and repair are the main industry in Brest, a French port located at the Department of Occupational and Environmental Diseases. The workers most exposed to asbestos were involved in this activity. Approximately 90% of compensated lung cancer patients were current or ex-smokers in the present study. Very few studies described smoking habits in this population (3). A synergistic interaction between asbestos and cigarette smoking is commonly accepted. A review of 23 studies was in favor of a multiplicative interaction (13). However, the multiplicative effect claimed by Hammond et al (12) has never been replicated and the hypothesis of a model somewhere between additive and multiplicative is the most probable (3). In most European countries, smoking is not involved in the recognition procedure of ARLC (17). However, in Denmark, any doubt regarding exposure of asbestos, heavy smoking leads to rejection of the procedure (17). If the patient consumed more than 7 g of tobacco per day or more than 10 packs a year, smoking was taken into account for the compensation of lung and laryngeal cancer. Those considerations also applied to cases of asbestosis if obstructive airways disease or chronic bronchitis was revealed in the past clinical history (17). However, the smoking factor is never retained in cases of mesothelioma or pleural plaques (17).

Adenocarcinoma was the most prevalent histological subtype in the present study (45.9%). Excess of adenocarcinoma in ARLC was shown in some studies (3). Nevertheless, recent well-controlled studies failed to show any significant differences between ARLC and non-ARLC (3). Adenocarcinoma is in fact the most frequent type of lung cancer. According to a recent review of the literature, histology has no significant value in determining whether or not lung cancer can be due to asbestos (3).

Notably, thoracic sarcoma was identified in the present study. To the best of our knowledge, if the link between lung carcinoma and asbestos exposure is well established, this is not true about thoracic sarcoma (6,8–11,18–20). Further investigations also identified two non-primary lung origin carcinomas of esophageal and laryngeal origin in the present study with controversial data regarding the association with asbestos exposure in the literature. In addition, there was no histological proof for 6.8% of the compensated lung cancers, diagnosis being solely based on radiologic data. Metastases of non-ARLC or non-carcinoma tumors cannot be excluded for these cases. In our opinion, histological analysis is a major parameter to evaluate the relationship between asbestos exposure and a lung malignant tumor. It may permit the distinction between a carcinoma of lung origin in which the link with asbestos exposure is well established, and other more doubtful asbestos-related primary or metastatic tumors.

In conclusion, the present results are globally in accordance with other studies on ARLC. Even if the relationship between smoking and asbestos exposure is not clear, the cases reported in the present study strongly argue for the crucial importance of smoking cessation in asbestos-exposed workers.

Thus, histological data have to be considered to evaluate the potent relationship between asbestos exposure and lung malignancy. Indeed, although the relationship between asbestos and lung carcinoma is well established, it is insufficiently proven regarding non-carcinoma type and/or cancer from extra-pulmonary primitive origin, except for mesothelioma.

Acknowledgements

The present study was supported by ‘La Ligue contre le cancer CD29’. We would like to also acknowledge ‘Omnium group’ for financial support and the pathologists of Brest and Local tumor tissue biobank BB-0033-00037 (‘CRB Santé’, CHRU Brest) for their collaboration in the present study.

References

1 

Eurogip: Cancers d'origine professionnelle: Quelle reconnaissance en Europe? http://www.eurogip.fr/images/publications/EUROGIP_RapportRecoCancerspro_49F.pdfApril 25–2010

2 

Tossavainen A: Asbestos, asbestosis, and cancer: The Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health. 23:311–316. 1997. View Article : Google Scholar : PubMed/NCBI

3 

Nielsen LS, Bælum J, Rasmussen J, Dahl S, Olsen KE, Albin M, Hansen NC and Sherson D: Occupational asbestos exposure and lung cancer - a systematic review of the literature. Arch Environ Occup Health. 69:191–206. 2014. View Article : Google Scholar : PubMed/NCBI

4 

Auerbach O, Garfinkel L, Parks VR, Conston AS, Galdi VA and Joubert L: Histologic type of lung cancer and asbestos exposure. Cancer. 54:3017–3021. 1984. View Article : Google Scholar : PubMed/NCBI

5 

Hiraoka K, Horie A and Kido M: Study of asbestos bodies in Japanese urban patients. Am J Ind Med. 18:547–554. 1990. View Article : Google Scholar : PubMed/NCBI

6 

Johansson L, Albin M, Jakobsson K and Mikoczy Z: Histological type of lung carcinoma in asbestos cement workers and matched controls. Br J Ind Med. 49:626–630. 1992.PubMed/NCBI

7 

Warnock ML and Isenberg W: Asbestos burden and the pathology of lung cancer. Chest. 89:20–26. 1986. View Article : Google Scholar : PubMed/NCBI

8 

Anttila S, Karjalainen A, Taikina-aho O, Kyyrönen P and Vainio H: Lung cancer in the lower lobe is associated with pulmonary asbestos fiber count and fiber size. Environ Health Perspect. 101:166–170. 1993. View Article : Google Scholar : PubMed/NCBI

9 

Hillerdal G, Karlén E and Aberg T: Tobacco consumption and asbestos exposure in patients with lung cancer: A three year prospective study. Br J Ind Med. 40:380–383. 1983.PubMed/NCBI

10 

Sluis-Cremer GK: The relationship between asbestosis and bronchial cancer. Chest. 78 Suppl:380–381. 1980. View Article : Google Scholar : PubMed/NCBI

11 

Weiss W: Lung cancer and occupational lung disease. Clin Chest Med. 2:289–300. 1981.PubMed/NCBI

12 

Hammond EC, Selikoff IJ and Seidman H: Asbestos exposure, cigarette smoking and death rates. Ann N Y Acad Sci. 330:473–490. 1979. View Article : Google Scholar : PubMed/NCBI

13 

Lee PN: Relation between exposure to asbestos and smoking jointly and the risk of lung cancer. Occup Environ Med. 58:145–153. 2001. View Article : Google Scholar : PubMed/NCBI

14 

Erren TC, Jacobsen M and Piekarski C: Synergy between asbestos and smoking on lung cancer risks. Epidemiology. 10:405–411. 1999. View Article : Google Scholar : PubMed/NCBI

15 

Samet JM, Epler GR, Gaensler EA and Rosner B: Absence of synergism between exposure to asbestos and cigarette smoking in asbestosis. Am Rev Respir Dis. 120:75–82. 1979.PubMed/NCBI

16 

Ahn YS and Kang SK: Asbestos-related occupational cancers compensated under the Industrial Accident Compensation Insurance in Korea. Ind Health. 47:113–122. 2009. View Article : Google Scholar : PubMed/NCBI

17 

Eurogip: Les maladies professionnelles liées à l'amiante en Europe. http://www.eurogip.fr/images/publications/EUROGIP- 24F-MPamiante.pdfMarch. 2006

18 

Hourihane DO and McCaughey WT: Pathological aspects of asbestosis. Postgrad Med J. 42:613–622. 1966. View Article : Google Scholar : PubMed/NCBI

19 

Raffn E, Lynge E and Korsgaard B: Incidence of lung cancer by histological type among asbestos cement workers in Denmark. Br J Ind Med. 50:85–89. 1993.PubMed/NCBI

20 

Whitwell F, Newhouse ML and Bennett DR: A study of the histological cell types of lung cancer in workers suffering from asbestosis in the United Kingdom. Br J Ind Med. 31:298–303. 1974.PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Uguen M, Dewitte JD, Marcorelles P, Loddé B, Pougnet R, Saliou P, De Braekeleer M and Uguen A: Asbestos-related lung cancers: A retrospective clinical and pathological study. Mol Clin Oncol 7: 135-139, 2017.
APA
Uguen, M., Dewitte, J., Marcorelles, P., Loddé, B., Pougnet, R., Saliou, P. ... Uguen, A. (2017). Asbestos-related lung cancers: A retrospective clinical and pathological study. Molecular and Clinical Oncology, 7, 135-139. https://doi.org/10.3892/mco.2017.1277
MLA
Uguen, M., Dewitte, J., Marcorelles, P., Loddé, B., Pougnet, R., Saliou, P., De Braekeleer, M., Uguen, A."Asbestos-related lung cancers: A retrospective clinical and pathological study". Molecular and Clinical Oncology 7.1 (2017): 135-139.
Chicago
Uguen, M., Dewitte, J., Marcorelles, P., Loddé, B., Pougnet, R., Saliou, P., De Braekeleer, M., Uguen, A."Asbestos-related lung cancers: A retrospective clinical and pathological study". Molecular and Clinical Oncology 7, no. 1 (2017): 135-139. https://doi.org/10.3892/mco.2017.1277
Copy and paste a formatted citation
x
Spandidos Publications style
Uguen M, Dewitte JD, Marcorelles P, Loddé B, Pougnet R, Saliou P, De Braekeleer M and Uguen A: Asbestos-related lung cancers: A retrospective clinical and pathological study. Mol Clin Oncol 7: 135-139, 2017.
APA
Uguen, M., Dewitte, J., Marcorelles, P., Loddé, B., Pougnet, R., Saliou, P. ... Uguen, A. (2017). Asbestos-related lung cancers: A retrospective clinical and pathological study. Molecular and Clinical Oncology, 7, 135-139. https://doi.org/10.3892/mco.2017.1277
MLA
Uguen, M., Dewitte, J., Marcorelles, P., Loddé, B., Pougnet, R., Saliou, P., De Braekeleer, M., Uguen, A."Asbestos-related lung cancers: A retrospective clinical and pathological study". Molecular and Clinical Oncology 7.1 (2017): 135-139.
Chicago
Uguen, M., Dewitte, J., Marcorelles, P., Loddé, B., Pougnet, R., Saliou, P., De Braekeleer, M., Uguen, A."Asbestos-related lung cancers: A retrospective clinical and pathological study". Molecular and Clinical Oncology 7, no. 1 (2017): 135-139. https://doi.org/10.3892/mco.2017.1277
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team